Forecast

The analysts' average price target is +5,36€ (+158,94%). The median is +5,58€ (+169,57%).

Buy	11
Hold	1
Sell	0

News Go to news feed

Equillium realigns leadership and focuses pipeline on drug candidate EQ504

Equillium reorganized management and the board, promoted Dr. Stephen Connelly to president while he remains active as CSO, and shortened the board; Daniel M. Bradbury remains chairman and Bruce Steel remains CEO. The company ended its collaboration on itolizumab and is concentrating on EQ504, a multimodal, non‑immunosuppressive aryl‑hydrocarbon receptor modulator with potential oral and inhaled formulations for inflammatory diseases. To strengthen the balance sheet, Equillium announced a prospectus supplement for share sales of up to $75 million, a private placement of up to $50 million (including a $30 million upfront payment), and the integration of cryptocurrencies into its treasury strategy. » More on de.investing.com
Equillium files prospectus supplement for stock offering of up to $75 million

Equillium has filed a prospectus supplement with the U.S. SEC for an offering and sale of common stock totaling up to $75 million under an open market sale agreement with LifeSci Capital. Under that agreement, 1,719,485 shares have already been sold, producing gross proceeds of $0.96 million. The company also reported a private placement of up to $50 million, with a $30 million advance for about 52.6 million shares at $0.57 per share and a potential additional $20 million contingent on milestone achievements. Equillium additionally announced plans to integrate cryptocurrencies into its treasury strategy; the stock is currently trading at $1.46 and the company has a market capitalization of $88 million. » More on de.investing.com
Equillium shares drop sharply after announcement of crypto strategy

Equillium's stock fell by 12.4% after the company announced plans to integrate cryptocurrencies into its treasury strategy. Investors reacted skeptically to the move away from its core business of developing therapies for autoimmune and inflammatory diseases, especially given the company's limited cash reserves. Equillium emphasized that it remains committed to its therapeutic pipeline and is implementing cost-cutting measures. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2008, Equillium has already paid 0,49€ in dividends. The last payout was in September 2008.

Financials

In the last quarter, Equillium had revenue of 0.00€ and net profit of −4.11m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	100,00%
Net profit	−4.11m	15,55%
EBITDA	−4.48m	7,56%

Fundamentals

Metric	Value
Market capitalization	+118.29m€
Number of shares	63.23m
52-week high/low	+3,04€ - +0,65€
Dividends	No
Beta	1,81
P/E ratio	−8,51
PEG ratio	−0,14
P/B ratio	+4,35
P/S ratio	0,00

Company profile

Equillium, Inc. ist ein in der klinischen Phase befindliches Biotechnologieunternehmen, das Produkte zur Behandlung schwerer Autoimmun- und Entzündungskrankheiten bzw. immunentzündlicher Erkrankungen mit ungedecktem medizinischen Bedarf entwickelt und vertreibt. Der führende Produktkandidat des Unternehmens ist Itolizumab (EQ001), ein monoklonaler Antikörper im klinischen Stadium, der auf den neuartigen Immun-Checkpoint-Rezeptor CD6 abzielt und sich in klinischen Phase-III-Studien zur Behandlung der akuten Transplantat-gegen-Wirt-Krankheit befindet; eine klinische Phase-Ib-Studie zur Behandlung von Asthma wurde abgeschlossen; eine klinische Phase-Ib-Studie zur Behandlung von Lupusnephritis wurde durchgeführt. Außerdem entwickelt es EQ101 zur Behandlung von kutanem T-Zell-Lymphom und Alopecia areata sowie EQ102 zur Behandlung verschiedener Magen-Darm-Erkrankungen. Das Unternehmen war früher als Attenuate Biopharmaceuticals, Inc. bekannt und änderte im Mai 2017 seinen Namen in Equillium, Inc. Equillium, Inc. wurde im Jahr 2017 gegründet und hat seinen Hauptsitz in La Jolla, Kalifornien.